Perspective Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-103.1M | $-79.3M | $-46.5M | $-10.8M | $-3.4M | $-3.4M | $-5.1M | $-6.7M |
| Depreciation & Amortization | $3.3M | $2.3M | $986.0K | — | — | — | — | — |
| Depreciation | — | — | $946.0K | $267.0K | $149.0K | $147.0K | $136.0K | $80.0K |
| Amortization | $7.0K | $7.0K | $7.0K | $7.0K | $37.0K | $38.0K | $50.0K | $50.0K |
| Stock-Based Compensation | $9.0M | $5.4M | $3.7M | $983.0K | $386.0K | $495.0K | $420.0K | $404.0K |
| Net Cash from Operating Activities | $-82.5M | $-18.3M | $-36.9M | $-10.4M | $-2.8M | $-3.6M | $-5.0M | $-5.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $12.7M | $54.4M | $1.1M | $282.0K | $381.0K | $273.0K | $444.0K | $337.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $41.2M | $-218.9M | $24.4M | $-29.0M | $-410.0K | $-287.0K | $401.0K | $1.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $10.3M | $289.4M | $785.0K | $28.0K | $64.7M | $994.0K | $7.4M | $521.0K |
| Net Change in Cash | $-31.0M | $52.2M | $-11.8M | $-39.4M | $61.4M | $-2.9M | $2.7M | $-3.3M |
| Free Cash Flow | $-95.2M | $-72.7M | $-38.0M | $-10.7M | $-3.2M | $-3.9M | $-5.5M | $-6.0M |